Share This Article:

Pharmacokinetics and Efficacy of Tilmicosin in the Treatment of Pasteurella haemolytica Bronchopneumonia in Calves

Abstract Full-Text HTML XML Download Download as PDF (Size:353KB) PP. 514-523
DOI: 10.4236/pp.2014.55061    4,278 Downloads   5,572 Views   Citations

ABSTRACT

Tilmicosin was administered intravenously and subcutaneously at a dose rate of 10 mg/kg bwt to determine its concentration in blood and bronchial secretion as well as its kinetic behavior in healthy and Pasteurella haemolytica type A1-infected calves. Sever acute bronchopneumonia was induced in 10 calves by inoculating them intra-tracheally with P. haemolytica type A1. The calves were treated with tilmicosin; 5 of these received the drug intravenously and the other 5 were injected subcutaneously. After a slow intravenous injection, the serum concentration-time curve indicated a two compartment open model with a mean elimination half-lives (t1/2bs) of 22.09 and 22.14 hours before and after infection, respectively. The mean residence time (MRT) corrected for a bolus injection was 2.25 and 2.20 hours and the mean MRTinf was 25.27 and 25.46 hours in healthy and P. haemolytica-infected calves, respectively. After subcutaneous injection, the drug was eliminated more slowly (before and after infection) from serum and bronchial secretions, with t1/2bs of (24.60 and 25.85 hours) and (33.74 and 31.78 hours), respectively. The apparent volume of distribution (Vd(area)) of tilmicosin was more than 1 litre·kg-1. The peak serum and bronchial secretions of tilmicosin concentration were (1.33 and 1.36 mg·ml-1) and (1.40 and 1.70 mg·ml-1) attained at (7.21 and 7.15 hours) and 7.11 and 7.10 hours) after subcutaneous injection, respectively. Tilmicosin was good secreted into bronchial secretions having AUCbronchial secretion/ AUCserum ratio of approximately 1:1.24 and 1:1.22 in healthy and P. haemolytica-

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Soliman, A. and Ali Ayad, A. (2014) Pharmacokinetics and Efficacy of Tilmicosin in the Treatment of Pasteurella haemolytica Bronchopneumonia in Calves. Pharmacology & Pharmacy, 5, 514-523. doi: 10.4236/pp.2014.55061.

References

[1] Vermeersch, H., Vandenbossche, G., Remon, J.P., Samyn, W., Vandendriessche, K., Sustronck, B., et al. (1996) Pharmacokinetics of Nebulized Sodium Ceftiofur in Calves. Journal of Veterinary Pharmacology and Therapeutics, 19, 152-154.
http://dx.doi.org/10.1111/j.1365-2885.1996.tb00029.x
[2] Scott, P.R. (1995) Efficacy of Strategic Tilmicosin Injection during an Outbreak of Respiratory Disease in Housed Beef Calves. British Veterinary Journal, 151, 587-589.
http://dx.doi.org/10.1016/S0007-1935(05)80030-2
[3] Dyer, R.M. (1982) The Bovine Respiratory Disease Complex: A Complex Interaction of Host, Environment and Infectious Factors. Compendium on Continuing Education for the Practicing Veterinarian, 4, S296-S304.
[4] Confer, A.W., Panciera, R.J., Corstvet, R.E., Rummage, J.A. and Fulton, R.W. (1984) Bovine Pneumonic Pasteurellosis: Effects of Culture Age of Pasteurella haemolytica Used as Live Vaccine. American Journal of Veterinary Research, 45, 2543-2545.
[5] Gibbs, H.A., Allan, E.M., Wiseman, A. and Selman, I.E. (1984) Experimental Production of Bovine Pneumonic Pasteurellosis. Research in Veterinary Science, 37, 154-166.
[6] Ames, T.R., Markham, R.J., Opuda-Asibo, J., Leininger, J.R. and Maheswaran, S.K. (1985) Pulmonary Response to Intratracheal Challenge with Pasteurella haemolytica and Pasteurella multocida. Canadian Journal of Comparative Medicine, 49, 395-400.
[7] Sustronck, B., Deprez, P., Muylle, E., Vermeersch, H., Vandenbossche, G. and Remon, J.P. (1995) Evaluation of the Nebulisation of Sodium Ceftiofur in the Treatment of Experimental Pasteurella haemolytica Bronchopneumonia in Calves. Research in Veterinary Science, 59, 267-71.
http://dx.doi.org/10.1016/0034-5288(95)90015-2
[8] Thompson, T.D., Laudert, S.B., Chamberland, S. and Lawrence, K. (1994) Micotil: Pharmacokinetics of Tilmicosin, a Semi-Synthetic Macrolide Antibiotic, in Acutely Pneumonic Cattle and Primary Bovine Alveolar Macrophages. 6th European Association for Vet Pharmacology and Therapeutics Congress, Edinburgh, 7-11 August 1994, 31-32.
[9] Scott, P.R. (1995) A Field Study of Respiratory Disease Affecting Housed Beef Calves in the United Kingdom. Cattle Practice, 3, 393-401.
[10] Musser, J., Mechor, G.D., Grohn, Y.T., Dubovi, E.J. and Shin, S. (1996) Comparison of Tilmicosin in with Long-Acting Oxytetracycline for Treatment of Respiratory Tract Disease in Calves. Journal of the American Veterinary Medical Association, 208, 102-106.
[11] Hartman, E.G. and Geryl, J. (1993) Comparison between the Minimal Inhibitory Concentration of Tilmicosin and Oxytetracycline for Bovine Pneumonic Pasteurella haemolytica Isolates. Veterinary Quarterly, 15, 184.
http://dx.doi.org/10.1080/01652176.1993.9694404
[12] Ziv, G., Shem-Tov, M., Glickman, A., Winkler, M. and Saran, A. (1995) Tilmicosin Antibacterial Activity and Pharmacokinetics in Cows. Journal of Veterinary Pharmacology and Therapeutics, 18, 340-345.
http://dx.doi.org/10.1111/j.1365-2885.1995.tb00601.x
[13] Friis, C. and Agerso, H. (1998) Penetration of Amoxycillin to the Respiratory Tract Tissues and Secretions in Actinobacillus pleuropneumoniae Infected Pigs. Research in Veterinary Science, 64, 251-257.
http://dx.doi.org/10.1016/S0034-5288(98)90134-5
[14] Carter, G.R. (1984) Diagnostic Procedures in Veterinary Bacteriology and Mycology. 4th Edition, Charles C. Thomas, Springfield, 129-142.
[15] Bennett, J.V., Brodie, J.L., Benner, E.J. and Kirby, W.M.H. (1966) Simplified, Accurate Method for Antibiotic Assay of Clinical Specimens. Applied and Environmental Microbiology, 14, 170-177.
[16] Thompson, T.D., Laudert, S.B., Chamberland, S. and Lawrence, K. (1994) Micotil: Pharmacokinetics of Tilmicosin, a Semi-Syntheticmacrolide Antibiotic, in Acutely Pneumonic Cattle and Primary Bovine Alveolarmacrophages. Proceedings of the 6th European Association of Veterinary Pharmacology and Toxicology, Edinburgh, 7-11 August 1994, 31.
[17] Baggot, J.D. (1987) Some Aspects of Clinical Pharmacokinetics in Veterinary Medicine. Journal of Veterinary Pharmacology and Therapeutics, 1, 5-18.
http://dx.doi.org/10.1111/j.1365-2885.1978.tb00300.x
[18] Gibaldi, M. (1984) Biopharmaceutics and Clinical Pharmacokinetics. 3rd Edition, Lea and Febiger, Philadelphia, 45-111.
[19] SAS Institute (1982) SAS User’s Guide. SAS Institute Inc., Cary, 191-193.
[20] Ramadan, A. (1997) Pharmacokinetics of Tilmicosin in Serum and Milk of Goats. Research in Veterinary Science, 62, 48-50.
http://dx.doi.org/10.1016/S0034-5288(97)90179-X
[21] Riviere, J.E., Craigmill, A.L. and Sundlof, S.F. (1990) Handbook of Comparative Pharmacokinetics and Residues of Veterinary Antimicrobials. CRS Press Inc., Boca Raton, 229.
[22] Barragry, T. (1991) Macrolide Antibiotics. Irish Veterinary News, May 1991.
[23] Gilman, A.G., Goodman, L.S. and Gilman, A. (1980) Goodman and Gilman’s: “The Pharmacological Basis of Therapeutics”. 6th Edition, Macmillan, New York, 21.
[24] Parker, R.M., Patel, R.K.P. and Simmons, H.A. (1994) The Pharmacokinetics of Tilmicosin in Sheep. Proceedings of the European Association for Veterinary Pharmacology and Toxicology, 6th International Congress, Edinburgh, 7-11 August 1994, 226-227.
[25] Ose, E.E. and Tonkinson, L.V. (1988) Single-Dose Treatment of Neonatal Calf Pneumonia with the New Macrolide Antibiotic Tilmicosin. Veterinary Record, 123, 367-369.
http://dx.doi.org/10.1136/vr.123.14.367
[26] Gourlay, R.N., Thomas, L.H., Wyld, S.G. and Smith, C.J. (1989) Effect of a New Macrolide Antibiotic (Tilmicosin) on Pneumonia Experimentally Induced in Calves by Mycoplasma bovis and Pasteurella haemolytica. Research in Veterinary Science, 47, 84-89.
[27] Mee, J.F. and O’Farrell, K. (1991) Tilmicosin and Calf Pneumonia. Veterinary Record, 128, 460.
http://dx.doi.org/10.1136/vr.128.19.460-a
[28] Laven, R. and Andrews, A.H. (1991) Long-Acting Antibiotic Formulations in the Treatment of Calf Pneumonia: A Comparative Study of Tilmicosin and Oxytetracycline. Veterinary Record, 129, 109-111.
http://dx.doi.org/10.1136/vr.129.6.109
[29] Smith, R.A., Gill, D.R. and van Koevering, M.T. (1993) Effects of Tilmicosin or Ceftiofur on Health and Performance of Stressed Stocker Cattle. Animal Science Research Report, Agricultural Experiment Station, Oklahoma State University, No. P 933, Stillwater, 308-311.
[30] Fodor, L., Varga, J., Gallowitsch, F., Horvath-Papp, I., Miklos, G., Lajcsak, A. and Harmath, A. (1993) Treatment of Calf Pneumonia with Tilmicosin. Acta Veterinaria Hungarica, 41, 41-49.
[31] Morck, D.W., Merrill, J.K., Thorlakson, B.E., Olson, M.E., Tonkinson, L.V. and Costerton, J.W. (1993) Journal of the American Veterinary Medical Association, 202, 273-277.
[32] Walters, J., Brown, D.R. and Tarrant, M.E. (1994) Efficacy of Pulmotil (Tilmicosin in Premix Form) against Naturally-Occurring Pneumonia in Growing-Fattening Pigs. Proceedings of the European Association for Veterinary Pharmacology and Toxicology, 6th International Congress, Edinburgh, 7-11 August 1994, 202-203.
[33] Allan, E.M., Gibbs, H.A., Wiseman, A. and Selman I.E. (1983) Pasteurella haemolytica Pneumonia in Weaned Housed Single Suckled Calves. Veterinary Record, 112, 327.
http://dx.doi.org/10.1136/vr.112.14.327
[34] Whiteley, L.O., Maheswaran, S.K., Weiss, D.J., Ames, T.R. and Kannan, M.S. (1992) Pasteurella haemolytica A1 and Bovine Respiratory Disease: Pathogenesis. Journal of Veterinary Internal Medicine, 6, 11-22.
http://dx.doi.org/10.1111/j.1939-1676.1992.tb00980.x
[35] Grunau, H. (1992) Field Trial of Tilmicosin for Endemic Bronchopneumonia of Beef Calves. Tierarztliche Hochschule Hannover, Hannover, 103.
[36] Grunau, H. and Klee, W. (1993) Field Trial of the Treatment of Enzootic Bronchopneumonia in Beef Calves with a New Macrolide Antibiotic, Tilmicosin. Praktische Tierarzt, 74, 210-218.
[37] Winter, T. and Hofmann, W. (1994) Treatment of Chronic Bronchopneumonia in Calves with the Macrolide Antibiotic Tilmicosin. PraktischeTierarzt, 75, 302-308.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.